Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report

Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report

IntroductionOsimertinib is recommended by major guidelines for use in the adjuvant setting in patients with EGFR mutation-positive NSCLC following the significant improvement in disease-free survival observed in the Phase III ADAURA trials. Due to limited real-world data in the adjuvant setting, lit...

Full description

Bibliographic Details
Main Authors: Myriam Mirza, Aseem Shrivastava, Cecile Matthews, Natasha Leighl, Calvin S. H. Ng, David Planchard, Sanjay Popat, Julia Rotow, Egbert F. Smit, Ross Soo, Masahiro Tsuboi, Fan Yang, Brendon Stiles, Christian Grohe, Yi-Long Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Oncology
Subjects:
osimertinib
non-small cell lung cancer
adjuvant treatment
EGFR mutation
recurrence
treatment sequencing
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1330468/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1330468/full

Similar Items